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Background: Bixa orellana L. has been traditionally used in Central and South America to treat a number of
ailments, including internal inflammation, and in other tropical countries like Malaysia as treatment for gastric ulcers
and stomach discomfort. The current study aimed to determine the major chemical constituents of the aqueous
extract of B. orellana (AEBO) and to evaluate the antihistamine activity of AEBO during acute inflammation induced
in rats.
Methods: Acute inflammation was produced by subplantar injection of 0.1 mL of 0.1% histamine into the right
hind paw of each rat in the control and treatment groups. The degree of edema was measured before injection
and at the time points of 30, 60, 120, 180, 240 and 300 min after injection. Changes of peritoneal vascular
permeability were studied using Evans blue dye as a detector. Vascular permeability was evaluated by the amount
of dye leakage into the peritoneal cavity in rats. To evaluate the inhibitory effect of AEBO on biochemical mediators
of vascular permeability, the levels of nitric oxide (NO) and vascular endothelial growth factor (VEGF) were
determined in histamine-treated paw tissues. The major constituents of AEBO were determined by gas
chromatography–mass spectrometry (GC-MS) analysis.
Results: AEBO produced a significant inhibition of histamine-induced paw edema starting at 60 min time point,
with maximal percentage of inhibition (60.25%) achieved with a dose of 150 mg/kg of AEBO at 60 min time point.
Up to 99% of increased peritoneal vascular permeability produced by histamine was successfully suppressed by
AEBO. The expression of biochemical mediators of vascular permeability, NO and VEGF, was also found to be
downregulated in the AEBO treated group. Gas chromatography–mass spectrometry (GC-MS) analysis revealed that
the major constituent in AEBO was acetic acid.
Conclusions: The experimental findings demonstrated that the anti-inflammatory activity of AEBO was due to its
inhibitory effect on vascular permeability, which was suppressed as a result of the reduced expression of
biochemical mediators (NO and VEGF) in tissues. Our results contribute towards the validation of the traditional use
of Bixa orellana in the treatment of inflammatory disorders.
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The Bixaceae family is one of the smallest plant families,
consisting only of one genus, Bixa. There are only five
species grouped under a single genus, and the most
common species is Bixa orellana, an evergreen shrub
grown not only because of its beautiful red flowers and
ornamental red spiny fruits, but also for its economic
value. Bixa orellana, also known as “annatto”, is native
to tropical America [1], but widely cultivated and
naturalized throughout the tropics, including Malaysia.
Bixa orellana is well known for its coloring agent and
medicinal value. The seeds are sources of food coloring
and a dye called annatto. Besides that, they are also used
as treatment for illnesses like gonorrhea and asthma and
have been traditionally used as gargle for sore throats.
The bark and root can be used to treat fever; the leaves
are used as a cure for snakebites, jaundice, diabetes and
hypertension, especially in Trinidad and Tobago, while
also being used as a postpartum medicine in Malaysia
[2]. The leaves of Bixa orellana have been reported
to have antimicrobial [3], antifungal, antileishmanial
[4], anticonvulsant, analgesic [5] and anti-inflammatory
activities [6].
Inflammation limits the damage to the body cells after
invasion by foreign organisms or mechanical injury, but if
goes uncontrolled and untreated, it becomes a threat
leading to other illnesses such as arthritis, cardiovascular
disease, asthma, and cancer. Histamine is one of the most
common inflammatory mediators; it causes symptoms of
allergic reactions that mostly involve acute inflammation
mediated by the H1 histamine receptor [7]. The histamine
H1 receptor is mainly expressed in endothelial cells,
smooth muscle cells and brain, and contributes to vaso-
dilation, increase of vascular permeability [8] and pain [9]
at the cellular level, while causing enhanced production of
intracellular calcium (Ca2+) and nitric oxide (NO) [10] at
the molecular level.
We have previously reported the ability of the aqueous
extract of Bixa orellana (AEBO) in suppressing inflam-
mation induced by carrageenan (data not published) and
bradykinin [6]. This study aimed to investigate whether
the anti-inflammatory activity of AEBO was caused by
the blocking of histamine action, and to determine the
involvement of two biochemical mediators, NO and vas-
cular endothelial growth factor (VEGF), in the reduction
of inflammation by AEBO.
Methods
Chemicals
The following chemicals and reagents were used: hista-
mine, loratadine, Evans Blue (Sigma Chemical Co. Ltd,
Selangor, Malaysia), nitrite/nitrate assay kit (Roche,
Kuala Lumpur, Malaysia) and Murine VEGF ELISA kit
(BioVision, USA).Plant material and extraction
Bixa orellana leaves were procured from around
Universiti Putra Malaysia. Leaves were identified and vou-
cher samples (NL16) were deposited at the Phytomedicine
Herbarium, Institute of Bioscience, Universiti Putra Ma-
laysia, Selangor. B. orellana leaves were dried in an oven
at 60°C for three consecutive days and ground into fine
powder. The aqueous extract was obtained by mixing the
powder together with distilled water at ratio 1:20, and kept
in a water bath (40°C) for 24 h, followed by filtration [6].
The filtrate was kept at −80°C and lyophilized using a
freeze drier, yielding 8.5% (w/w). At the time of use, the
lyophilized extract was dissolved in distilled water at the
desired concentration.
Experimental animals
Experiments were conducted using male Sprague–
Dawley rats weighing 200–250 g, purchased from
Northern RK Supplier, Malaysia and housed at the Ani-
mal House of the Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia. The animals were
divided into groups of six individuals (n = 6) and kept in
plastic cages at room temperature (23 ± 1°C) in a 12-h
light:dark cycle, with free access to standard chow diet
and water. The animals were acclimatized to the labora-
tory conditions for at least 1 week before the beginning
of each experiment. All experiments complied with the
current guidelines for the care and use of laboratory
animals and were approved by the Animal Care and Use
Committee (ACUC), Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia (ACUC NO. UPM/
FPSKPADS/F01-00176).
Gas chromatography – mass spectrometry analysis
The aqueous extract of B. orellana leaves (AEBO) was
analyzed by gas chromatography–mass spectrometry
(GC-MS-QP5050A-Shimadzu). A Zebron ZB-FFAP ca-
pillary column with length 30.0 m x diameter 0.25 mm
and film thickness 0.25 μm was used. The column oven
temperature was kept at 50°C for 3 min, then increased
up to 250°C at a rate of 20°C/min and held at 250°C for
20 min. The carrier gas (helium) was introduced into
the column at a flow rate of 1.0 mL/min. Injector and
interface temperatures were set to 250°C each. AEBO
(1 μL) was injected manually into the GC-MS in splitless
mode. Compounds were identified by comparing their
mass spectra with those in the NIST library and by com-
paring their retention times with those of authentic
standards.
Histamine-induced paw edema in rats
The effect of oral administration of AEBO was
determined by injection of histamine in the subplantar
region of the right hind paw, according to the method
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pretreated with AEBO at doses of 50 and 150 mg/kg, for
4 consecutive days, before being injected with 0.1 mL
histamine (0.1%). Control animals received a similar vol-
ume of vehicle (0.1 mL). Loratadine (10 mg/kg), a hista-
mine H1 antagonist, was used as the reference drug and
administered 60 min before histamine injection on the
fourth day. Edema was identified by the changes in paw
volume, measured using a plethysmometer (Model 7140,
Ugo Basile, Italy) before histamine administration and at
60, 120, 180 and 240 min after histamine injection.
Histamine-induced intraperitoneal vascular permeability assay
To evaluate the changes of intraperitoneal vascular perme-
ability induced by histamine, Evans blue dye was used as an
indicator according to the method previously described by
Whittle [13]. Rats were injected intravenously with 5 mL/kg
of 1% Evans blue solution 60 min after the oral admin-
istration of AEBO, vehicle, or loratadine. Rats were killed
30 min after the intraperitoneal injection of histamine. The
concentration of Evans blue in the peritoneal fluid was
measured via spectrophotometry at 610 nm wavelength.
Histamine-induced nitric oxide (NO) assay
NO was measured according to the method of Moshage
et al. [14], using a commercially available Nitrite/Nitrate
Colorimetric Kit (Roche). For this assay, 0.1 mL of 0.1% his-
tamine was injected intraplantarly on the fourth day and
the paw tissue obtained was deproteinized with 35%
sulfosalicylic acid. The tissues were homogenized and
centrifuged to obtain the supernatant. Nitrate (NO3
-) wasFigure 1 Major chemical constituents present in the aqueous extractconverted into nitrite (NO2
-) after reacting with nitrate re-
ductase. Total nitrite was measured using Griess reagent
with 1:1 ratio and read at OD 540 nm. The sum of nitrite
and nitrates obtained from this procedure represented the
NO concentration in paw tissue (μM/g wet weight of
tissue).
Histamine-induced vascular endothelial growth factor
(VEGF) assay
The concentration of VEGF in rat hind paw was
determined using Murine VEGF ELISA Kit (BioVision).
Analysis of VEGF was performed using standard ELISA
methodology according to the kit’s manual. Briefly, paw
tissue was excised after 6 h of histamine-induced inflam-
mation. The tissues were homogenized in pre-chilled lysis
buffer containing protease inhibitor. The homogenate was
centrifuged and VEGF level was determined from the
supernatant obtained. All assays were performed in tripli-
cate and results were expressed in ng/mL protein.
Statistical analysis
All data were reported as mean ± SEM; n represented the
number of animals in each group. Statistical comparisons
were made by ANOVA followed by Tukey’s multiple com-
parison test. P values < 0.05 were considered significant.Results
Chemical constituents of AEBO
Several organic compounds were detected in AEBO by
GC-MS (Figure 1). Six major compounds were identified:of Bixa orellana leaves.
Table 1 Chemical constituents of AEBO, detected by
GC-MS, with relative retention time (tR)






2 2-Butanamine 7.767 2.57 Amine
3 Acetic acid 8.292 19.95 Organic acid
8 Pentanoic acid 9.583 3.75 Fatty acid
24 Phenol 11.600 3.95 Carbolic acid
25 Pantolactone 11.817 1.53 Lactone
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pentanoic acid (valeric acid) (tR; 9.583 min), phenol
(tR; 11.600 min), pantolactone (tR; 11.817 min), and
benzoic acid (tR; 13.850 min) (Table 1).Effect of AEBO on histamine-induced paw edema in rats
Exposure of rat’s hind paw to histamine resulted in a
marked increase of paw tissue weight and skin thickness.
Paw weight significantly declined upon oral administra-
tion of AEBO (50 and 150 mg/kg) or loratadine (10 mg/
kg) at 60 min time point compared with the non-treated
group (Figure 2). Moreover, the changes were also sig-
nificant for the dose of 150 mg/kg of AEBO compared
to the non-treated group, from 180 min onwards. Al-
though the paw volume reached its peak 60 min after
histamine injection, the maximal edema inhibition was
observed 300 min after the administration of 150 mg/kg
of AEBO (76.0%). The percentages of inhibition
produced by 150 mg/kg of AEBO at each time point
(starting from 60 min) were 60.3%, 51.8%, 67.3%, 75.0%
and 76.0%.Figure 2 Effect of AEBO on histamine-induced paw edema in rats. Da
every 60 min until 300 min. *P < 0.05, significantly different from negative cEffect of AEBO on histamine-induced peritoneal vascular
permeability
As shown in Figure 3, both doses of AEBO (50 and
150 mg/kg) notably inhibited the histamine-induced in-
crease of dye leakage into the peritoneal cavity, with an
inhibitory rate up to 99%. The potency of AEBO was
similar to that of loratadine (91.1% inhibition).
Effect of AEBO on histamine-induced NO production
Production of NO in rat’s paw was markedly increased
in response to histamine (46.2 ± 1.8 μM), but was signifi-
cantly suppressed by both doses of AEBO (P < 0.05)
(Figure 4). The concentrations of NO were reduced to
29.7 ± 1.2 μM and 19.7 ± 1.4 μM after the administration
of 50 and 150 mg/kg of AEBO, respectively. On the
other hand, loratadine, the reference drug, also signifi-
cantly inhibited the NO production induced by hista-
mine. However, the inhibition rate of loratadine was not
as high as that obtained with both doses of AEBO (50
and 150 mg/kg). This indicated that AEBO had an
inhibitory effect on histamine-induced NO production.
Effect of AEBO on histamine-induced VEGF production
Figure 5 shows that oral administration of AEBO signifi-
cantly suppressed histamine-induced VEGF production
in rat’s paw. As observed, the highest dose of AEBO
(150 mg/kg) had a greater effect (55.9% inhibition)
compared with the reference drug, loratadine (~11.2%
inhibition). On the other hand, 50 mg/kg of AEBO only
showed 36.6% inhibition compared with the non-treated
group.
Discussion
The present study demonstrated that the aqueous
extract of Bixa orellana leaves had anti-inflammatory
activity, as shown by the suppression of vascular fluidta are expressed as mean ± SEM, n = 6. Paw volume was measured
ontrol (histamine only).
Figure 3 Effect of AEBO on histamine-induced peritoneal
vascular permeability. Evans blue dye was collected and measured
by spectrophotometer. Data are presented as mean ± SEM, n = 6.
*P < 0.05, significantly different from NC (negative control).
Figure 5 Influence of AEBO on histamine-induced VEGF
production in rat’s paw. Data are presented as mean ± SEM, n = 6.
*P < 0.05, significantly different from NC (negative control).
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mine activities, revealed by decreased paw volumes and
almost normalized peritoneal vascular permeability, were
suspected to be aided by the suppression of other
permeability-regulating substances (NO and VEGF).
In our preliminary study, B.orellana exhibited the abil-
ity to suppress the inflammatory activities of a number
of mediators, with AEBO having inhibited up to 99% of
paw edema induced by carrageenan (data not published).
Indeed, when bradykinin was later used to induce acute
inflammation in the same rat models, it was confirmedFigure 4 Effect of AEBO on histamine-induced NO production
in rat’s paw. Paw tissue was homogenized and the supernatant
was assayed by the Griess reaction. Data are presented as mean ±
SEM, n = 6. *P < 0.05, significantly different from control.that up to 82% of the increased vascular permeability
was successfully alleviated upon administration of AEBO
[6]. Histamine is one of the inflammogens that
contributes to acute inflammation and increase of vascu-
lar permeability [15]. The present study documents for
the first time the ability of AEBO to suppress the
histamine-induced inflammation in rats. Paw edema
assay is a useful tool for investigating agents with poten-
tial anti-inflammatory capabilities. The present study
showed that exposure of rat’s paw to histamine triggered
an elevation in fluid extravasations from microvessels in
the vicinity, an event that led to tissue swelling. The
results showed that AEBO was able to significantly sup-
press histamine-induced paw edema in rats, and this may
probably be due to the inhibition of the H1 receptor or
other signaling molecules down its pathway. Histamine H1
receptor expressed in endothelial cells of blood vessels is
important for regulating vascular permeability [10], and
increased permeability occurs once it is activated.
Inflammatory processes are also characterized by an in-
crease in microvascular permeability to macromolecules.
Leakage of Evans blue dye into the peritoneal cavity
indicated the formation of gaps or pores in the wall of the
peritoneal microvessels, large enough for a significant por-
tion of macromolecules to pass through. The administra-
tion of AEBO resulted in the retention of the normal
endothelial barrier function during histamine challenge,
having prevented the leakage of approximately 99% of the
Evans blue dye into the peritoneal cavity. Based on these
outcomes, it was demonstrated that AEBO displayed sig-
nificant antihistamine activity, through inhibition of the
vascular permeability processes. This could also be related
to the suppression of other permeability-regulating
molecules that lead to inflammation.
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known as key regulators of permeability and binding to
their receptors trigger an increase in vascular permeabil-
ity [16]. Upregulation and downregulation of VEGF ex-
pression contributes to abnormal angiogenesis indirectly
leading to vascular hyperpermeability [17]. Furthermore,
overproduction of VEGF also contributes to progression
to other diseases such as coronary disease [18] and
cancer [19]. Ghosh and colleagues [20] demonstrated
that histamine enhanced the production of VEGF during
acute inflammation. VEGF release and its above-
mentioned effects on vascular permeability and cellular
infiltration could contribute to edema formation. Thus,
it is very important to regulate VEGF production in cells
either by suppression when it is overproduced or vice
versa. Our results showed that the oral administration of
AEBO in rats decreased the histamine-induced VEGF
production, indicating that AEBO may have the poten-
tial to regulate vascular permeability by monitoring the
expression of VEGF.
Nitric oxide (NO) is a signaling molecule that is
synthesized from L-arginine by NO synthase [21]. It is well
recognized that NO plays an important role in maintaining
the normal physiological function of vascular tissues. It has
been previously reported that histamine increased vascular
permeability by activating NO production [22]. In addition,
Mayhan [23] also demonstrated that nitric oxide was
involved in increased macromolecular extravasation
induced by histamine in the hamster cheek pouch. In
addition, endothelial nitric oxide synthase (eNOS) was
found to play a major role in vascular leakage during acute
inflammation in vivo [24]. Thus, suppression of NO pro-
duction may help reduce acute inflammation. From the
present study, it was observed that more than 50% of the
NO elevation caused by histamine could be alleviated by
AEBO. This further supports its action as an anti-
inflammatory agent.
Raga and colleagues [25] successfully isolated ishwarane,
phytol, polyprenol and a mixture of stigmasterol and
sitosterol from the dichloromethane extract of air-dried
leaves of B. orellana. The current GC-MS analysis revealed
six known chemical constituents. However, based on the
literature, only four of them are known to exhibit pharma-
cological activity. Acetic acid is an organic acid that has
been reported to possess antifungal [26] and antibacterial
properties [27]. Pentanoic acid (valeric acid) is a sedative,
anticonvulsant and mood-stabilizing agent [28]; whereas
phenol was reported to have anesthetic/analgesic [29] and
antiseptic [30] activities. Benzoic acid possesses antibacter-
ial [31] and antifungal properties [32]. As for their anti-
inflammatory contribution, a low concentration of acetic
acid (0.3 mg/mL) has been shown to inhibit histamine
release from guinea pig lung mast cells when stimulated by
both antigen (ovalbumin) and ionophore A23187 [33]. It isknown that allergic reactions develop from large inflamma-
tory responses caused by the release of mediators, includ-
ing histamine, during degranulation of mast cells. There is
also evidence of histamine itself acting as an inducer of
mast cell degranulation [34]. This could have happened in
our rat model, where histamine was injected into animals
to induce inflammation.
All of these constituents may or may not play an import-
ant role in the anti-inflammatory activity. Nonetheless, the
possibility of the minor compounds exhibiting anti-
inflammatory properties cannot be excluded.
Conclusions
Our results confirmed that the aqueous extract of B.
orellana had antihistamine activities, as demonstrated
by the suppression of increased vascular permeability
reflected in the decreased paw volume and Evans blue dye
leakage. It appeared that this permeability modulation by
AEBO also involved the reduction of biochemical
mediators such as NO and VEGF. We considered that the
active principle contained in the aqueous extract may play
a role in its anti-inflammatory activity. Whether or not it
acts by stabilizing mast cells remains to be elucidated.
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